title: Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder.
abstract: OBJECTIVE
  To investigate the effects of mirabegron (50 mg once daily for 12 weeks) in treatment-naïve women with overactive bladder (OAB) based on urodynamic studies.
  
  
  METHODS
  This was an open-labeled, single-center, prospective study involving 65 recruited outpatients. The OAB symptom score was used for assessing the severity of subjective symptoms. Urodynamic studies, including uroflowmetry, cystometry, and pressure flow study, were conducted to evaluate objective symptoms. The first desire to void, maximum cystometric capacity, and occurrence of detrusor overactivity were measured as storage function parameters, whereas maximum flow rate, detrusor pressure at Qmax, and postvoid residual urine volume were assessed as voiding function parameters.
  
  
  RESULTS
  A total of 60 patients with a mean age of 72.3 years (50-86 years) were included in the analysis. The subjective symptom parameter (ie, the mean OAB symptom score) decreased significantly from 9.4 to 6.2 points (P <.001). In objective symptom parameters, both the first desire to void and maximum cystometric capacity significantly improved after treatment, and detrusor overactivity disappeared in 14 of 35 patients (40.0%) compared with that at baseline (P <.01). The voiding function parameters (ie, mean maximum flow rate, detrusor pressure at Qmax, and postvoid residual urine volume) did not significantly change, demonstrating that mirabegron does not inhibit voiding function.
  
  
  CONCLUSIONS
  Mirabegron improves storage function and subjective symptoms, without influencing voiding function, in women with OAB.
authors.affiliation: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: yoshi44@med.nagoya-u.ac.jp.
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Matsukawa
authors.affiliation: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Shun
authors.initials: S
authors.lastname: Takai
authors.affiliation: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Funahashi
authors.affiliation: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Tokunori
authors.initials: T
authors.lastname: Yamamoto
authors.affiliation: Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Momokazu
authors.initials: M
authors.lastname: Gotoh
mesh_terms: D000083:Acetanilides / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology*; D014554:Urination; D014563:Urodynamics; D064804:Urological Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000083:Acetanilides; D013844:Thiazoles; D064804:Urological Agents; C520025:mirabegron